Us2.ai receives FDA clearance for Us2.v2,transforming…

NOVATO, CA – January 30, 2014 – Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the pricing of its initial public offering of 5,760,369 shares of its common stock at an initial public offering price of $21.00 per share, before underwriting discounts. The shares are expected to begin trading on The NASDAQ Global Select Market on January 31, 2014 under the ticker symbol “RARE.” All of the shares of common stock are being offered by Ultragenyx. In addition, Ultragenyx has granted the underwriters a 30-day option to purchase up to an additional 864,054 shares of common stock to cover over-allotments, if any.